Loading...
RVLP.Q logo

RVL Pharmaceuticals plcOTCPK:RVLP.Q Stock Report

Market Cap US$111.0
Share Price
US$0.000001
My Fair Value
n/a
1Y0%
7D0%
1D
Portfolio Value
​
View

RVL Pharmaceuticals plc

OTCPK:RVLP.Q Stock Report

Market Cap: US$111.0

RVL Pharmaceuticals (RVLP.Q) Stock Overview

Operates as a specialty pharmaceutical company in the United States, Argentina, and Hungary. More details

RVLP.Q fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Risk Analysis

Does not have a meaningful market cap ($111)

Latest financial reports are more than a year old

Shares are highly illiquid


RVLP.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

RVL Pharmaceuticals plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for RVL Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.000001
52 Week HighUS$0.0001
52 Week LowUS$0.000001
Beta0
1 Month Change0%
3 Month Change0%
1 Year Change0%
3 Year Change-99.90%
5 Year Change-99.90%
Change since IPO-99.90%

Recent News & Updates

Recent updates

Analysis Article • Aug 16

RVL Pharmaceuticals plc (NASDAQ:RVLP) Analysts Just Cut Their EPS Forecasts Substantially

One thing we could say about the analysts on RVL Pharmaceuticals plc ( NASDAQ:RVLP ) - they aren't optimistic, having...
Analysis Article • May 13

Analysts Just Made A Major Revision To Their RVL Pharmaceuticals plc (NASDAQ:RVLP) Revenue Forecasts

Market forces rained on the parade of RVL Pharmaceuticals plc ( NASDAQ:RVLP ) shareholders today, when the analysts...
Analysis Article • May 12

RVL Pharmaceuticals plc (NASDAQ:RVLP) Doing What It Can To Lift Shares

RVL Pharmaceuticals plc's ( NASDAQ:RVLP ) price-to-sales (or "P/S") ratio of 2.3x might make it look like a buy right...
Analysis Article • Apr 20

RVL Pharmaceuticals (NASDAQ:RVLP) Is Making Moderate Use Of Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Jan 05

Is RVL Pharmaceuticals (NASDAQ:RVLP) Using Debt Sensibly?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Oct 18

RVL Pharmaceuticals sees Q3 net sales of UPNEEQ for eye treatment about $10M

New Jersey-based RVL Pharmaceuticals (NASDAQ:RVLP) announced on Tuesday that the company generated nearly $10M net product sales for its eye disease therapy Upneeq in 3Q 2022, implying a sequential growth of ~19%. Upneeq is indicated for adults with acquired blepharoptosis or droopy eyelids, ~3,500 cumulative unique medical aesthetics practices placed orders for UPNEEQ through the end of the third quarter 2022, a 59% increase from the end of the second quarter 2022. With 3Q net sales growth adding ~$24.4M for the nine months of 2022, RVL (RVLP) anticipates fourth quarter 2022 UPNEEQ net product sales to grow approximately 20% - 40% over the third quarter 2022, representing sales of approximately $12 - $14 million.
Seeking Alpha • Sep 22

RVL Pharmaceuticals: Chapter 2 - A Developing Quandary

Summary RVL Pharmaceuticals shares have performed admirably over the last quarter. UPNEEQ appears well short of its ambitious revenue guidance for Q4, 2022. Q3 promises to present further challenges to the UPNEEQ growth narrative. Liquidity will be an existential challenge for RVLP unless, maintaining discipline on expenditures, its UPNEEQ revenues solidify at a high level. This article provides a Q2 update to June's article, "RVL Pharmaceuticals: Chapter 1 Gives A Mixed Picture" ("Chapter 1"). RVL Pharmaceuticals (RVLP) is a small/micro cap stock with big ambitions. It is working to parlay its FDA approved UPNEEQ into an entry to the aesthetics market. The June article reviewed RVLP's plans for making headway in this new market. I questioned whether the company could meet its guided revenue targets. As I will discuss, it is indeed struggling to meet its goals. For Q2, 2022, RVLP shares have outperformed during an awful market environment. RVLP reported Q2 earnings on 08/11/2022. Its shares have been on a tear for the whole month of August continuing into September. Shares closed 07/2022 Data by YCharts at $1.44. Despite a slight recent downdraft as I write on 09/19/2022, shares are trading at $2.89. RVLP has doubled over the last ~six weeks. Seeking Alpha's RVLP news feed offers nothing to account for this dramatic move. However in my review of RVLP's Q2, 2022 10-Q, I ran across a possible explanation. Under a subheading "equity financing" (p. 20) it stated: ...on August 4, 2022, the Company entered into a series of share subscription agreements (collectively, the "Share Subscription Agreements") with Athyrium Opportunities IV Co-Invest 2 LP ("Athyrium"), Avista Healthcare Partners, L.P. ("Avista"), Brian Markison, Chief Executive Officer, and James Schaub, Executive Vice President and Chief Operating Officer, (together, the "Equity Purchasers") pursuant to which the Company sold and issued to the Equity Purchasers, in a private placement (the "Private Placement"), an aggregate of 15,451,612 ordinary shares of the Company, nominal value $0.01 per share (the "Ordinary Shares"), at a purchase price of $1.55 per Ordinary Share, the closing market trading price on August 4, 2022. As reflected by the price chart above, $1.55 was a nice anchor price for these shares which had been trading in a range from a low of ~$1.00 to a high of ~$2.00 since the start of the year. The fact that investors, including the CEO and COO were willing to make such large purchases at $1.55 seems to have emboldened the market. The market for RVLP shares since 08/04/2022 has launched upwards in terms of both volume and price. The share purchases were not only helpful in terms of volume, they were also most apt in terms of pricing. RVLP's Q2 earnings were only so-so as reflected by Seeking Alpha's earnings headline below: GAAP EPS of -$0.14 beats by $0.07, revenue of $8.45M misses by $0.07M A revenue miss during a key early quarter when RVLP was trying to establish its credibility in aesthetics could have been received poorly. Significant share purchases from the CEO and COO help to defray any such narrative. UPNEEQ's Q2, 2022 net sales were $8.4 million, well short of its guided for Q4, 2022 net sales. In 01/2022 RVLP issued its guidance pegging net sales for UPNEEQ during Q4, 2022 to fall in the range between $20-$25 million. At the time it issued this guidance RVLP was selling UPNEEQ exclusively as a medical treatment being offered through medical channels. Its intent at the time was to open up sales to take place in the aesthetics market. It hoped by doing so to significantly expand its market. Success in this new approach is critical to RVLP. That is the reason I have been so focused on its quarterly earnings. During Q1, 2022, it generated net UPNEEQ sales of $5.9 million. In doing so it achieved a 90% increase over its Q4, 2021 UPNEEQ sales. Now for its latest Q2, 2022 report it has net UPNEEQ sales of $8.4 million, a quarterly increase of 42%. Revenues of $8.4 million for Q2 are well short of the low end of its guided range of $20-25 million for Q4. With decelerating growth rate from 90% to 42% it is hard to see it reaching its guided goal. Q3 promises to present even greater challenges to the UPNEEQ growth narrative. RVLP's Q2, 2022 earnings call (the "Call"), reporting earnings as of 06/30/2022, did not take place until 08/11/2022. By that time RVLP had pretty good visibility into Q3 UPNEEQ sales trajectory. An analyst question as to the phasing of UPNEEQ sales during the 3rd and 4th quarters and as to whether RVLP wanted to update its Q4 guidance for UPNEEQ was a real eye-opener. I was hoping that this might generate a serious discussion of how RVLP hoped to reach its guided target. Not so. Rather in terms of guidance, CEO Markison advised that RVLP was sticking to its previous range albeit he made it clear that it was the lower end of the range which seemed doable. In this regard he explained: ...we're remaining on, on at the lower end of our initial range and I think it has to do a bit with phasing. We know that July was a heavy vacation month. Other folks have said at the macros in the industry certainly support it and our expanded team originally was scheduled to be out July 05. We took the time to train them during the month of July and they really didn't hit the street until the end of the month, the very last week. So, I think we're still on the low end of the range of what we gave as guidance almost a year ago before we launched into aesthetics. Feel really good about it, but I would think that our third quarter will be tempered a bit by what we seeing in July, certainly supported by the industry. This is a bit of a downer for RVLP bulls. It had intended to get its expanded sales team working during July. Instead it pulled them back for additional training. Expanded training could be a good thing; time will tell. A need for expanded training is nonetheless concerning. RVLP has prepared for potential ongoing losses with a recent hefty cash raise. The liquidity section, at pg. 10-11 of RVLP's Q2, 2022 10-Q, provides cautionary advice that investors need to take to heart. For example it states: ...there is a substantial doubt as to the Company's ability to operate as a going concern. The Company's ability to continue as a going concern will require it to obtain additional funding, generate positive cash flow from operations and/or enter into strategic alliances or sell assets.
Seeking Alpha • Aug 30

RVL Pharma in pact with Revision Skincare to broaden access to products

RVL Pharmaceuticals plc (NASDAQ:RVLP), the maker of Upneeq eye disease therapy, and Revision Skincare, an Irving, Texas-based seller of skin care products, announced a partnership on Tuesday to widen market access to their product offerings. Through the partnership, Revision’s skincare brands D·E·J Eye Cream, Revox Line Relaxer, and RVLP’s FDA-approved therapy for low-lying lids, Upneeq, will be available for more patients and healthcare providers across the U.S. Two companies have planned joint marketing efforts to address highly unmet consumer needs within the medical aesthetics industry. Revision Skincare’s “strong history of innovation and passion for skin health aligns with our core directive around ocular medical aesthetics,” RVLP’s Chief Executive Brian Markison noted, welcoming the partnership. RVLP was previously known as Osmotica Pharmaceuticals which acquired rights for Upneeq in 2017 from RevitaLid.
Seeking Alpha • Aug 11

GAAP EPS of -$0.14 beats by $0.07, revenue of $8.45M misses by $0.07M

press release (NASDAQ:RVLP): Q2 GAAP EPS of -$0.14 beats by $0.07. Revenue of $8.45M (-26.6% Y/Y) misses by $0.07M. “Our recent financing and addition of Alisa Lask to our Board of Directors are strong signals of our growing belief in UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%. Ms. Lask brings over 20 years of commercial experience in pharmaceuticals and medical aesthetics. Of note, she held senior leadership roles at Galderma and Allergan and currently holds the position of Chief Commercial Officer at RION, a development stage biotechnology company focused on regenerative medicine in medical and aesthetic applications. Our recent track record of growth and growing evidence of social proof have enabled us to attract outstanding talent from the industry and entertain a number of potentially exciting partnerships,” stated Brian Markison, Chief Executive Officer of RVL Pharmaceuticals plc.
Seeking Alpha • Jul 07

RVL Pharma posts preliminary 42% sales growth for eye treatment

Citing preliminary financials, New Jersey-based RVL Pharmaceuticals (NASDAQ:RVLP) announced on Thursday that the company generated nearly $8.4M net product sales for its eye disease therapy Upneeq in 2Q 2022, implying a sequential growth of ~42%. Upneeq is indicated for adults with acquired blepharoptosis or droopy eyelids. From February through June of 2022, the company has received Upneeq orders from about 2,200 cumulative unique medical aesthetics practices. With 2Q net sales growth adding ~$14.4M in the first six months of 2022, RVL (RVLP) reaffirmed its 4Q guidance with $20M – $25M net product sales projected for Upneeq. Sales of Upneeq and Parkinson's disease drug Osmolex account for the topline of RVL (RVLP). The company sold the product rights for Osmolex in January 2021.
Analysis Article • Jul 04

RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Seeking Alpha • Jun 15

RVL Pharmaceuticals: Chapter 1 Gives A Mixed Picture

RVL focused its initial launch of UPNEEQ for adults with acquired blepharoptosis on medical treatment. UPNEEQ's critical first quarter addressing the aesthetics side is now in the books. Despite positive UPNEEQ revenues, RVL is no more than a hold.
Analysis Article • Apr 01

New Forecasts: Here's What Analysts Think The Future Holds For RVL Pharmaceuticals plc (NASDAQ:RVLP)

Celebrations may be in order for RVL Pharmaceuticals plc ( NASDAQ:RVLP ) shareholders, with the analysts delivering a...
Seeking Alpha • Mar 30

RVL Pharmaceuticals: A Makeover For An Ugly Duckling

Hapless Osmotica renamed itself RVL Pharmaceuticals. It has a novel business model which vastly simplifies its business. Encouragingly, recent company estimate pegs 2022 Q4 UPNEEQ net revenues at $20-$25 million.
Seeking Alpha • Dec 14

Osmotica: A Different Breed Of Cat

Having closed on the sale of its legacy business, Osmotica had UPNEEQ, arbaclofen ER, and little else. Despite having downsized, Osmotica is still incurring significant and growing ongoing expenses. Running UPNEEQ as a standalone business is challenging and may be doomed to failure. Before deciding on UPNEEQ's investment merits, consider its forthcoming launch into the ocular aesthetics market.
Analysis Article • Aug 20

Osmotica Pharmaceuticals (NASDAQ:OSMT) Takes On Some Risk With Its Use Of Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Jul 16

Osmotica: Paring Down, Focusing On UPNEEQ

Osmotica is scraping along the bottom of its 52 week price chart. Osmotica's recent strategic transaction has solidified the company's miniaturization. Osmotica's 06/2021 Strategic Sale Call focuses on an upbeat UPNEEQ-centric future.

Shareholder Returns

RVLP.QUS PharmaceuticalsUS Market
7D0%5.6%-3.3%
1Y0%37.6%22.3%

Return vs Industry: RVLP.Q underperformed the US Pharmaceuticals industry which returned 40% over the past year.

Return vs Market: RVLP.Q underperformed the US Market which returned 22.5% over the past year.

Price Volatility

Is RVLP.Q's price volatile compared to industry and market?
RVLP.Q volatility
RVLP.Q Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement10.1%
Market Average Movement7.2%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: RVLP.Q's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine RVLP.Q's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/aBrian Markisonwww.rvlpharma.com

RVL Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, Argentina, and Hungary. It focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults.

RVL Pharmaceuticals plc Fundamentals Summary

How do RVL Pharmaceuticals's earnings and revenue compare to its market cap?
RVLP.Q fundamental statistics
Market capUS$111.00
Earnings (TTM)-US$68.27m
Revenue (TTM)US$36.92m
0.0x
P/S Ratio
0.0x
P/E Ratio

Is RVLP.Q overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RVLP.Q income statement (TTM)
RevenueUS$36.92m
Cost of RevenueUS$6.53m
Gross ProfitUS$30.39m
Other ExpensesUS$98.66m
Earnings-US$68.27m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did RVLP.Q perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/09 17:58
End of Day Share Price 2026/06/09 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

RVL Pharmaceuticals plc is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Louise ChenCantor Fitzgerald & Co.
David SteinbergJefferies LLC
Glen SantangeloJefferies LLC